New drug ORB-011 tested in advanced cancer patients
NCT ID NCT05947474
First seen Feb 18, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This early-stage study tests a new drug, ORB-011, in 55 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check if the drug is safe and to find the best dose for future studies. Participants will be monitored for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
MD Anderson Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.